News

Thermo Fisher Scientific Inc. announced that it has completed its acquisition of Patheon, a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical…
Read More...

Gilead Sciences, Inc. and Kite Pharma, Inc. announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Kite for $180.00 per share in…
Read More...

Daiichi Sankyo Company, Limited and Boston Pharmaceuticals, Inc. announced that they have entered into a worldwide licensing agreement for Daiichi Sankyo's novel RET inhibitor, DS-5010.…
Read More...

Kedrion Biopharma and Kamada Ltd., two leading human-derived protein therapeutics companies, announced that KEDRAB™ has received U.S. Food and Drug Administration (FDA) approval for…
Read More...

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and…
Read More...

Otsuka Pharmaceutical and Mylan have entered into a license agreement between their respective subsidiaries, Otsuka Novel Products GmbH (ONPG) and Mylan Pharmaceuticals Private Limited…
Read More...

Genentech announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for emicizumab…
Read More...

ViraCyte, LLC, a clinical stage biopharmaceutical company developing cellular immunotherapies for severe infections, announced publication of positive data from a Phase 2 clinical trial…
Read More...

Ethris GmbH announced a five-year strategic research collaboration with AstraZeneca and its global biologics research and development arm, MedImmune. The collaboration is focused on…
Read More...

Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved BESPONSA® (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell…
Read More...

Medivir AB and Ascletis announce that Ascletis has licensed the exclusive rights to develop, manufacture and commercialize Medivir's nucleotide polymerase inhibitor for hepatitis C,…
Read More...

Samsung Bioepis announced that it has entered into a strategic collaboration agreement with Takeda Pharmaceutical Company Limited to jointly fund and co-develop multiple novel biologic…
Read More...

Teva Pharmaceutical Industries announced the launch of generic Axiron®1 (testosterone) topical solution CIII, 30 mg/1.5 mL, in the U.S. Testosterone topical solution CIII is a…
Read More...

Valeant Pharmaceuticals International announced that the U.S. Food and Drug Administration (FDA) confirmed it intends to issue a Voluntary Action Indicated (VAI) inspection…
Read More...

Shire announces that the Marketing Authorization Application (MAA) for lifitegrast, submitted on 07 August 2017, has been validated by the UK as the Reference Member State involved in…
Read More...

Regeneron Pharmaceuticals announced that a Phase 3 study evaluating suptavumab (REGN2222), an antibody to respiratory syncytial virus (RSV), did not meet its primary endpoint of…
Read More...

After a series of thorough tests with the European Medicines Verification Organization (EMVO) for connection to the European Hub, Adents is now one of only two official “Certified…
Read More...

Array BioPharma, a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer,…
Read More...

A new consortium, led by Oxford BioMedica, will take part in a two-year, £2m project focused on gene and cell therapy manufacturing. Other partners include the Cell and Gene…
Read More...

Takeda Pharmaceutical Company Limited announced a collaboration with Stanford University to form the Stanford Alliance for Innovative Medicines (Stanford AIM), which will help transform…
Read More...